Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pseudomonas Infections Clear all

Conditions: Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
Interventions: AZLI 75 mg three times daily (TID), Placebo three times daily (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 34
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more

Conditions: Carbapenem-Resistant Enterobacteriaceae
Interventions: Rectal swab collection; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Indianapolis, Indiana • Detroit, Michigan

Conditions: Cystic Fibrosis
Interventions: Inhaled AR-501, Inhaled Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more

Conditions: Cystic Fibrosis
Interventions: Tobramycin Inhalation Powder; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 21
States / cities: Mobile, Alabama • Los Angeles, California • Sacramento, California + 18 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions: AZLI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 12 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions: Cystic Fibrosis patients; Other
Lead sponsor: Landon Pediatric Foundation; Other
Eligibility: 1 Year to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ventura, California

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 9 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland • Milwaukee, Wisconsin

Conditions: Cystic Fibrosis
Interventions: AZLI, Placebo to match AZLI, Tobramycin inhalation solution; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more

Conditions: Health Care Associated Infection, Hand Hygiene
Interventions: Standard care, Protocolized care; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Year to 18 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions: Chlorhexidine; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Brain and Central Nervous System Tumors
Interventions: TGFa-PE38 immunotoxin, conventional surgery; Biological · Procedure
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Pneumonia
Interventions: Murepavadin, Two anti-pseudomonal antibiotics; Drug
Lead sponsor: Polyphor Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina

Conditions: Cystic Fibrosis
Interventions: azithromycin 250 mg tablets, placebo tablets; Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 6 Years to 18 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 31
States / cities: Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more

Conditions: Cystic Fibrosis
Interventions: Piperacillin-tazobactam combination product; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 8 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more

Conditions: Pseudomonas Aeruginosa, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Zafer Soultan; Other
Eligibility: 5 Years to 19 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Pseudomonas Infection
Interventions: Ciprofloxacin (Cipro, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions: Aztreonam Lysine for Inhalation; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
U.S. locations: 64
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more

Conditions: Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions: SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Surgical Procedure, Unspecified
Interventions: Personalized Body-Worn Alcohol Dispenser; Device
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cystic Fibrosis
Interventions: Gallium nitrate, Normal Saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more

Conditions: Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Interventions: Rev-56 for Inhalation, Placebo: Normal saline; Combination Product · Drug
Lead sponsor: Revagenix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Persistent Infection, Cystic Fibrosis
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more

Conditions: Cystic Fibrosis
Interventions: 13C urea breath test Kit; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

Volatile Organic Compounds in Cystic Fibrosis

Tissue Collection From People With Cystic Fibrosis

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Reducing Intraoperative Infection Transmission in the Pediatric Operating Room

Animal-Assisted Visitation Program Chlorhexidine Trial

TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Reducing ESKAPE Transmission in the Operating Room

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF